Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 5,348 matching trials from the live ClinicalTrials.gov search.
Filters: Milwaukee, Wisconsin Clear all
Completed Phase 2 Interventional Results available

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

NCT03913455
View directory record Official record
Conditions
Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Interventions
Guadecitabine, Carboplatin
Drug
Lead sponsor
Shadia Jalal, MD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Indianapolis, Indiana • Muncie, Indiana • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 21, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT04044768
View directory record Official record
Conditions
Synovial Sarcoma, Myxoid Liposarcoma
Interventions
afamitresgene autoleucel (previously ADP-A2M4)
Genetic
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
17
States / cities
Duarte, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

NCT01191255
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Failure
Interventions
ferric citrate, ca acetate, sevelamer carbonate, placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
52
States / cities
Tempe, Arizona • Los Angeles, California • Riverside, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 21, 2026, 2:42 PM EDT
Terminated Phase 3 Interventional Results available

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02470585
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasm
Interventions
Veliparib, Paclitaxel, Carboplatin, Placebo to Veliparib
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
135
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

NCT02066415
View directory record Official record
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
Erenumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
34
States / cities
La Jolla, California • Newport Beach, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 21, 2026, 2:42 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Individuals on Hormone Therapy Breast Cancer Screening Pilot

NCT06383026
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Cancer Screening, Survey/Interview, Focus Group
Diagnostic Test · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
30 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 21, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

NCT02100891
View directory record Official record
Conditions
Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, CNS Tumors
Interventions
Allogeneic HCT, Donor NK Cell Infusion
Procedure · Drug
Lead sponsor
Monica Thakar
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

NCT01609790
View directory record Official record
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Trebananib
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
243
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 172 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 21, 2026, 2:42 PM EDT
Not yet recruiting Phase 4 Interventional

Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction

NCT07158606
View directory record Official record
Conditions
Hemophilia A With Inhibitor
Interventions
efanesoctacog alpha, Emicizumab
Drug
Lead sponsor
Versiti Blood Health
Other
Eligibility
0 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Recurrence of Diverticulitis

NCT00545740
View directory record Official record
Conditions
Diverticulitis
Interventions
SPD476 (1.2g), SPD476 (2.4 g), SPD476 (4.8 g), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
46
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Oral TP-1454

NCT04328740
View directory record Official record
Conditions
Advanced Solid Tumor, Anal Cancer
Interventions
TP-1454 monotherapy
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

NCT03193190
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

NCT00120406
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
Zilver® PTX™ Drug Eluting Vascular Stent, Angioplasty
Device · Procedure
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
44
States / cities
Mountain View, California • Oceanside, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 21, 2026, 2:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
43
States / cities
Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Vascular Malformations and Abnormalities of Growth

NCT01105676
View directory record Official record
Conditions
Abnormality
Interventions
skin biopsy
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Months and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 21, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

NCT02498535
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide 160 ppm
Drug
Lead sponsor
Novoteris, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

NCT02238925
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
Interventions
CPX-351
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana • Westwood, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 21, 2026, 2:42 PM EDT
Terminated Not applicable Interventional Results available

Dual Site Left Ventricular (LV) Pacing

NCT00944125
View directory record Official record
Conditions
Congestive Heart Failure, LV Dysfunction
Interventions
Dual Site LV Pacing, BiV Pacing
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Lake Geneva, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 4 Interventional

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

NCT00144768
View directory record Official record
Conditions
Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie's Syndrome
Interventions
laronidase
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Los Angles, California • Hartford, Connecticut • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution

NCT02298842
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Platelets stored in InterSol, Platelets stored in Plasma
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

NCT02148705
View directory record Official record
Conditions
Thermal Burns
Interventions
NexoBrid, Standard of Care (SOC), Gel Vehicle
Drug · Procedure
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 77 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 21, 2026, 2:42 PM EDT